Roche and Mylan settle a scrap over Herceptin, clearing path to a global launch of a knockoff drug
Two weeks ago Roche shares jumped on the news that the pharma giant had scored winning Phase III data supporting the combination of Herceptin and Perjeta in fighting early-stage breast cancer. And today, Roche and Mylan are announcing that they’ve agreed to a settlement of their long-running dispute over a biosimilar of Herceptin, leaving Mylan with boasting rights for its shot at becoming the first company to get a knockoff onto the US market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.